STOCK TITAN

Utmost Group PLC (TLSI) files Schedule 13G showing 5.71% ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. Schedule 13G reports that Utmost Group PLC beneficially owns 3,503,385 shares of common stock, equal to 5.71% of the class as of 03/31/2026. The filing notes ownership declined by more than 1% versus 09/30/2025 due to an increase in outstanding shares. The report is signed by Ian Maidens, Group CFO, on 05/05/2026.

Positive

  • None.

Negative

  • None.

Insights

Utmost Group PLC holds a 5.71% stake in TriSalus as of 03/31/2026.

Utmost Group PLC reports sole voting and dispositive power over 3,503,385 shares, representing 5.71% of the class. The filing explicitly ties a >1% ownership decline to an increase in outstanding shares between 09/30/2025 and 03/31/2026.

Cash‑flow treatment or planned dispositions are not disclosed in the excerpt; subsequent filings would state any sale programs or schedules.

The Schedule 13G is a passive reporting format by a regulated non‑U.S. institution.

The filer indicates reliance on a foreign regulatory scheme and certifies comparability to specified U.S. equivalents. The filing includes identification of a subsidiary, Utmost Luxembourg S.A., and is signed by the Group CFO on 05/05/2026.

This is a disclosure of beneficial ownership; it does not, by itself, signal trading intent.

Beneficial ownership 3,503,385 shares as of 03/31/2026
Percent of class 5.71% as of 03/31/2026
Comparison date 09/30/2025 prior reference date for >1% ownership decline
Filing signatory Ian Maidens - Group CFO signature dated 05/05/2026
Schedule 13G regulatory
"On 31 March 2026, Utmost Group PLC held 3,503,385 units of TriSalus Life Sciences's common shares"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially owned regulatory
"Amount beneficially owned: 3,503,385 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 3,503,385"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
foreign regulatory scheme regulatory
"the foreign regulatory scheme applicable to (J) A non-U.S. institution"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Utmost Group PLC report in TriSalus (TLSI)?

Utmost Group PLC reports beneficial ownership of 3,503,385 shares, representing 5.71% of TriSalus common stock as of 03/31/2026. The filing states sole voting and dispositive power over these shares.

Did Utmost Group PLC increase or decrease its ownership in TLSI?

The filing states Utmost's ownership decreased by more than 1% compared to 09/30/2025, citing an increase in the company's outstanding shares as the cause rather than additional disposals by Utmost.

Who signed the Schedule 13G for TLSI and when?

The Schedule 13G was signed by Ian Maidens, Group CFO of Utmost Group PLC, on 05/05/2026, certifying the foreign regulatory comparability statement included in the filing.

Does the Schedule 13G indicate Utmost plans to sell TLSI shares?

The filing discloses beneficial ownership and voting/dispositive power for 3,503,385 shares but does not state any planned sales or distribution methods; no disposition program is described in the provided excerpt.





89680M101

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On 31 March 2026, Utmost Group PLC held 3,503,385 units of TriSalus Life Sciences's common shares, representing 5.71% of the outstanding shares. Compared to 30 September 2025, the ownership of Utmost Group PLC in the company decreased by more than 1% as a result of an increase in outstanding shares of the company.


SCHEDULE 13G



Utmost Group PLC
Signature:/s/ Ian Maidens
Name/Title:Ian Maidens - Group CFO
Date:05/05/2026